Aditi Shastri

Dr. Aditi Shastri


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ASAditi Shastri
Aditi Shastri
GCGaurav Choudhary
Gaurav Choudhary
MTMargarida Teixeira
Margarida Teixeira
SGShanisha Gordon-Mitchell
Shanisha Gordon-Mitchell
NRNandini Ramachandra
Nandini Ramachandra
Amit VermaAmit Verma
Amit Verma
Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are associated with disease-initiating stem cells that are not eliminated by conventional therapies. Transcriptomic analysis of stem and progenitor populations in MDS and AML demonstrated overexpression of STAT3 that was validated in an independent cohort. STAT3 overexpression was predictive of a shorter survival and worse clinical features in a large MDS cohort. High STAT3 expression signature in MDS CD34+ cells was similar to known preleukemic gene signatures. Functionally, STAT3 inhibition by a clinical, antisense oligonucleotide, AZD9150, led to reduced viability and increased apoptosis in leukemic cell lines. AZD9150 was rapidly incorporated by primary MDS/AML stem and progenitor cells and led to increased hematopoietic differentiation. STAT3 knockdown also impaired leukemic growth in vivo and led to decreased expression of MCL1 and other oncogenic genes in malignant cells. These studies demonstrate that STAT3 is an adverse prognostic factor in MDS/AML and provide a preclinical rationale for studies using AZD9150 in these diseases.

21 September 2021 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
NRNora E. Rahmani
Nora E. Rahmani
NRNandini Ramachandra
Nandini Ramachandra
SSSrabani Sahu
Srabani Sahu
NGNadege Gitego
Nadege Gitego
ALAndrea Lopez
Andrea Lopez
Amit VermaAmit Verma
Amit Verma
The BCL2-inhibitor, Venetoclax (VEN), has shown significant anti-leukemic efficacy in combination with the DNMT-inhibitor, Azacytidine (AZA). To explore the mechanisms underlying the selective sensitivity of mutant leukemia cells to VEN and AZA, we used cell-based isogenic models containing a common leukemia-associated mutation in the epigenetic regulator ASXL1. KBM5 cells with CRISPR/Cas9-mediated correction of the ASXL1G710X mutation showed reduced leukemic growth, increased myeloid differentiation, and decreased HOXA and BCL2 gene expression in vitro compared to uncorrected KBM5 cells. Increased expression of the anti-apoptotic gene, BCL2, was also observed in bone marrow CD34+ cells from ASXL1 mutant MDS patients compared to CD34+ cells from wild-type MDS cases. ATAC-sequencing demonstrated open chromatin at the BCL2 promoter in the ASXL1 mutant KBM5 cells. BH3 profiling demonstrated increased dependence of mutant cells on BCL2. Upon treatment with VEN, mutant cells demonstrated increased growth inhibition. In addition, genome-wide methylome analysis of primary MDS samples and isogenic cell lines demonstrated increased gene-body methylation in ASXL1 mutant cells, with consequently increased sensitivity to AZA. These data mechanistically link the common leukemia-associated mutation ASXL1 to enhanced sensitivity to VEN and AZA via epigenetic upregulation of BCL2 expression and widespread alterations in DNA methylation.

17 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
ASAditi Shastri
Aditi Shastri
JWJustin Wheat
Justin Wheat
SASachee Agrawal
Sachee Agrawal
NCNirjhar Chaterjee
Nirjhar Chaterjee
KPKith Pradhan
Kith Pradhan
JSJayanthi Shastri
Jayanthi Shastri
The novel coronavirus SARS-CoV2 has been observed to cause a higher incidence and greater severity of disease in males, as seen in multiple cohorts across the globe. The reasons for gender disparity in disease severity is unclear and can be due to host factors. To determine whether males have delayed viral clearance after infection, we evaluated the time to clearance in symptomatic patients tested by serial oropharyngeal/nasopharyngeal swabs followed by RT-PCR at a reference lab in Mumbai, India. A total of 68 subjects with median age of 37 years (3-75 range) were examined and included 48 (71%) males and 20 (29%) females. We observed that females were able to achieve viral clearance significantly earlier than males, with a median difference of 2 days in achieving a negative PCR result (P value = 0.038). Furthermore, examination of 3 families with both male and female patients followed serially, demonstrated that female members of the same household cleared the SARS-CoV2 infection earlier in each family. To determine reasons for delayed clearance in males, we examined the expression patterns of the SARS-CoV2 receptor, Angiotensin-converting enzyme 2 (ACE2), in tissue specific repositories. We observed that the testes was one of the highest sites of ACE2 expression in 3 independent RNA expression databases (Human Protein Atlas, FAMTOM5 and GETx). ACE2 was also determined to be highly expressed in testicular cells at the protein levels. Interestingly, very little expression of ACE2 was seen in ovarian tissue. Taken together, these observations demonstrate for the first time that male subjects have delayed viral clearance of SARS-CoV2. High expression of ACE2 in testes raises the possibility that testicular viral reservoirs may play a role in viral persistence in males and should be further investigated.

26 November 2019 in Cancer
Verified
Journal Article
Open access
PDF file
USUrvi A. Shah
Urvi A. Shah
NSNishi Shah
Nishi Shah
BQBaozhen Qiao
Baozhen Qiao
AAAna Acuna‐Villaorduna
Ana Acuna‐Villaorduna
KPKith Pradhan
Kith Pradhan
MJMurali Janakiram
Murali Janakiram
Background: Globally, 5 million to 10 million people are infected with human T‐cell leukemia virus type 1, which causes adult T‐cell leukemia/lymphoma (ATLL) in 2% to 5% of the carriers. ATLL is a rare but extremely aggressive malignancy that can be challenging to diagnose. Very little data exist on the incidence patterns of ATLL in the United States.Methods: ATLL cases reported to the National Program of Cancer Registries, the Surveillance, Epidemiology, and End Results (SEER) program, and the New York State Cancer Registry were used for the study. Age‐adjusted incidence rates were calculated by age, race/ethnicity, sex, and year of diagnosis. The 5‐year survival rate was compared among race/ethnicity groups with the SEER data.Results: During 2001‐2015, 2148 ATLL cases were diagnosed in the United States, 18% of which were in New York State. New York State had the highest incidence rate for ATLL, with a rising trend especially among non‐Hispanic blacks (NHBs), whereas the incidence was stable across the remainder of the United States. NHBs were diagnosed at a younger median age (54 years) and had a shorter overall survival (6 months). In New York City, only 22.6% of the ATLL cases diagnosed were born in North America.Conclusions: This is the largest epidemiological study of ATLL in the United States and shows a rising incidence in New York City. NHBs have a younger age at presentation and poor overall survival. The rising incidence is largely due to NHBs originating from the Caribbean.

14 September 2021 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
SCSamarpana Chakraborty
Samarpana Chakraborty
LSLauren C. Shapiro
Lauren C. Shapiro
SOSofia de Oliveira
Sofia de Oliveira
BRBianca Rivera-Pena
Bianca Rivera-Pena
Amit VermaAmit Verma
Amit Verma
ASAditi Shastri
Aditi Shastri
Even though genetic perturbations and mutations are important for the development of myeloid malignancies, the effects of an inflammatory microenvironment are a critical modulator of carcinogenesis. Activation of the innate immune system through various ligands and signaling pathways is an important driver of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The DAMPs, or alarmins, which activate the inflammasome pathway via the TLR4/NLR signaling cascade causes the lytic cell death of hematopoietic stem and progenitor cells (HSPCs), ineffective hematopoiesis, and β-catenin-induced proliferation of cancer cells, leading to the development of MDS/AML phenotype. It is also associated with other myeloid malignancies and involved in the pathogenesis of associated cytopenias. Ongoing research suggests the interplay of inflammasome mediators with immune modulators and transcription factors to have a significant role in the development of myeloid diseases, and possibly therapy resistance. This review discusses the role and importance of inflammasomes and immune pathways in myeloid malignancies, particularly MDS/AML, to better understand the disease pathophysiology and decipher the scope of therapeutic interventions.

1 March 2015 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
SMSantosh Murthy
Santosh Murthy
YMYogesh Moradiya
Yogesh Moradiya
SSShreyansh Shah
Shreyansh Shah
ASAditi Shastri
Aditi Shastri
EBEric M. Bershad
Eric M. Bershad
JSJose I. Suarez
Jose I. Suarez